MARKET

IBIO

IBIO

Ibio
AMEX
1.080
+0.030
+2.86%
Opening 09:47 03/18 EDT
OPEN
1.072
PREV CLOSE
1.050
HIGH
1.130
LOW
1.070
VOLUME
8.91K
TURNOVER
0
52 WEEK HIGH
52.00
52 WEEK LOW
1.021
MARKET CAP
3.76M
P/E (TTM)
-0.0396
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IBIO last week (0311-0315)?
Weekly Report · 17h ago
Weekly Report: what happened at IBIO last week (0304-0308)?
Weekly Report · 03/11 09:40
Weekly Report: what happened at IBIO last week (0226-0301)?
Weekly Report · 03/04 09:41
Ibio Inc Advances Portfolio with Strategic Asset Sale
TipRanks · 02/26 13:13
iBio stock jumps on sale of preclinical PD-1 agonist antibody program
IBio stock jumps on sale of preclinical PD-1 agonist antibody program to Otsuka Pharmaceutical. The biopharmaceuticals company's shares rose over 13% premarket on Monday. IBio's pipeline will now be comprised entirely of immuno-oncology candidates.
Seeking Alpha · 02/26 13:04
iBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka
IBio has sold its assets related to its early-stage programmed cell death protein-1 agonist program to Otsuka Pharmaceutical Co. The transaction closed on Sunday. PD-1 is a pivotal checkpoint in the immune system. IBio will receive an upfront payment of $1 million.
Dow Jones · 02/26 12:55
Press Release: iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
IBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka -- Deal includes $1 million upfront and potential future milestone payments -- iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates. IBio is selling its assets related to its early-stage programmed cell death protein 1 agonist program.
Dow Jones · 02/26 12:45
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
IBio will receive $1 million upfront and potential future milestone payments. Otsuka acquired iBio's assets related to its early-stage programmed cell death protein 1 (PD-1) agonist program. PD-1 is a pivotal checkpoint in the immune system. IBio’s pipeline will now be comprised entirely of promising immuno-oncology candidates.
Forward News · 02/26 12:45
More
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and PD-1 Agonist. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Webull offers Ibio Inc stock information, including AMEX: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.